
Deep Tech VC 🚀 | Managing Partner @alumniventures | 2x Founder CEO | Ex-Innovation @Nike 👟 | @georgetown @berkeleyhaas 📚 | Opinions mine.
Palo Alto, CA
Joined August 2013
- Tweets374
- Following2.2K
- Followers638
- Likes749
Matt Caspari retweeted
Today, we are excited to introduce Ladon, a state-of-the-art biological foundation model that predicts disease trajectory and treatment response in patients. There is immense complexity in the individual biology of every patient. Two patients can have the same diagnosis and receive the same treatment, yet have very different outcomes: one responds well and lives for years, while the other’s disease continues to progress. Understanding and resolving this heterogeneity to predict outcomes is how we accelerate our delivery of medicines for patients and unlock clinical trial abundance.
Ladon is our first step towards this future: one where we can learn more from every patient enrolled so that we can run smaller, faster trials with higher success rates. We built it to give drug developers quantitative support on billion-dollar clinical trial decisions. Today we're excited to share Ladon's capabilities in our blog and technical report.
Ladon is a 3B parameter model trained on millions of RNA-seq samples spanning decades of technical and biological variation across tissues and species. Ladon beats gene expression baselines, established biomarkers, and existing RNA foundation models at predicting patient prognosis and therapeutic response in 140+ oncology tasks, including external validation on past clinical trials. This is significant because clinical trials are fundamentally generalization problems. We show that Ladon-derived predictions are robust across indications, treatments, and sequencing platforms.
Reach out if you’d like to get started with the model today!
Read more about Ladon in the blog: blank.bio/introducing-ladon
Find more technical details in the white paper: blank.bio/introducing-ladon
Matt Caspari retweeted
Robotics are supposed to be a step change in labor economics.
To actually deliver that you have to completely change the cost curve.
Fully vertically integrated.
Purpose-built robotics.
Not humanoids.
We’ve done that at @cytronic_ai
~80% lower cost
and facilities that run 24/7.
Thanks @alex @twistartups for having me on.
Matt Caspari retweeted
We're pulling back the curtain on our aircraft on 14 Sept at @AFA_Air_Space's Air, Space & Cyber Conference next month.
See you there.
Matt Caspari retweeted
Today, we are announcing our $31M seed financing at Apollo Atomics.
The $26M equity is led by FCVC with participation from Y Combinator, TeleSoft Partners, Alumni Ventures, Pelion Venture Partners, Duke Capital Partners, Robinhood Ventures, and Nucleation Capital. $5M of equipment financing is provided by Oak Ridge Financial.
Apollo Atomics is the only nuclear company that can deliver high power output nuclear reactors (>80 MW) on a truck. The higher power density is the strongest argument for cost effectiveness and mass manufacturing in the nuclear industry today. We achieve this without relying on exotic/scarce fuel, unqualified materials, or high regulatory uncertainty.
Achieving that goal is a mirage if you don’t build the right company. With Drew Walker, we have assembled an extremely talent dense team with Excellence, Intensity, and Execution at its core. We are running a low power reactor demonstrator within MIT and now building a full scale 1 MW reactor prototype under commercial reactor conditions. We work directly with the U.S. Nuclear Regulatory Commission to support a commercial deployment in 2028.
Apollo Atomics is not hardware in vacuum, we are building software solutions for autonomous reactor control, licensing support, and reactor modeling to reduce OpEx and deployment timeline.
Deeply grateful to our early investors for supporting our mission when no one else believed particularly Genesis Fund, Arjun Gupta, and New Era Ventures, to our early supporters within Massachusetts Institute of Technology, MIT Sandbox Innovation Fund Program, TNT, MIT Department of Nuclear Science and Engineering.
Excited to have many brilliant individual investors supporting our mission including Paul Graham, Evan Meagher, CFA, Philip Johnston, Ray Rothrock, Matteo Franceschetti
Matt Caspari retweeted
Had a great conversation with @alex Wilhelm on @twistartups about what we’re building at @cytronic_ai.
We went deep on the economics of physical AI, why traditional fulfillment gets more expensive as it scales, and how robotics can fundamentally change the cost curve.
A typical 3PL charges ~$3–$3.50 to fulfill an order.
At Cytronic, that same order can be ~$0.70.
And fulfillment is only the beginning.
Full conversation:
youtube.com/watch?v=qW9wdH8_…
Matt Caspari retweeted
Excited to announce @andromedasurg's Series A led by @Standard_Cap. Could not imagine a better partner as we bring autonomous surgery to the world.
We raised $15M in this round and $30M in total. We are launching now and you will be hearing a lot more from us soon!
Announcing our $15 million Series A, led by @Standard_Cap with participation from @ycombinator, @Vox_Capital, and other notable funds and angels. This brings our total funding to $30 million.
We’re building an autonomous surgery platform to give every patient access to the world’s best surgeon. It’s like a sous chef for surgery. The surgeon sets the plan and the platform executes.
Surgeons have successfully treated 44 patients with our product so far. This round will fund initial launch and initial scale-up. We're cleared to launch in New Zealand and Canada, with more clearances expected soon.
Surgery is a $3.7 trillion global market, and a better application for autonomy than driving. But while autonomous vehicles are already widespread on public roads, most surgical robots have very limited intelligence.
That changes now.
Surgery will soon become one of the most important applications of physical AI. Andromeda is ready to lead the way.
svpost.com/articles/andromed…
Matt Caspari retweeted
We believe brands shouldn't have to become Amazon to ship like Amazon.
Today, we’re unveiling @cytronic_ai, a robotic fulfillment network helping ecommerce brands lower costs by up to 80%, deliver faster, and scale without giving up control of their customers.
Matt Caspari retweeted
Brands shouldn't have to become Amazon to ship like Amazon.
Today we're unveiling @cytronic_ai — robotic fulfillment that helps ecommerce brands lower costs by up to 80%, deliver faster, and scale without giving up control of their customers.
Matt Caspari retweeted
Tech Weekend June 2026 Recap:
VC Panel: How VCs Make Decisions — From First Meeting to Term Sheet. @mat
Gary Gardner, Founder & CEO of Lead Generation Hubs, moderated the session with a simple premise: most fundraising decisions are made in rooms founders never see, and a "no" often has far less to do with the pitch than with everything happening around it. The hour was about making that hidden process visible.
Matt Caspari (@deeptechvc) Managing Partner at @alumniventures, leads the firm's Deep Tech and Strawberry Creek Ventures funds and invests from seed to pre-IPO. Having raised over $100M as a two-time founder himself, he walked the room through what actually happens inside the partnership meeting after you leave. His takeaway for founders was about the Champion: your real job in the room is to give the partner who believes in you everything they need to defend the deal when you're no longer there to do it yourself.
Victoria Smith, Partner at @ZacuaVentures, focused on the earliest stages across PropTech, ConTech, and AI-native software. Bringing both an operator's and an investor's lens, she helped founders decode investor feedback that isn't direct — what "keep us posted" really signals — and how to run a process so multiple investors move at the same time. Her message was about Momentum: a round comes together when interest is concurrent, not when it's chased one conversation at a time.
Allen Smith, Founder & Managing Partner at Musa Capital, invests in tech-enabled businesses built by diverse founding teams and brings a decade in go-to-market from LinkedIn and Microsoft. He spoke to what investors decide about you before you ever start pitching, and offered a practical playbook for international founders on how to set up, position, and build credibility when raising in the US market.
From there the session moved into the term sheet — what genuinely matters to negotiate and what founders tend to over-index on. The panel's shared view was that the negotiation itself is the first real test of the partnership: how you handle it signals how you'll work together long after the money is in the bank.
Thank you to Matt Caspari, Victoria Smith, Allen Smith, and Gary Gardner for pulling back the curtain on how venture decisions really get made, and for giving our founders the tactical tools to navigate the path to a "yes."
Tech Weekend returns September 10–11, 2026 with more conversations like this one.
Details and sign up at techweekend.org
Matt Caspari retweeted
Coming up at Tech Weekend June 2026:
VC Panel: How VCs Make Decisions — From First Meeting to Term Sheet What really happens on the other side of the table when you're raising.
This session covers:
• What VCs decide about you before you start pitching
• Why most good meetings don't turn into checks — and what changes that
• What happens inside the partnership meeting after you leave the room
• How to run a process so multiple investors move at the same time
• How to read investor feedback when they're not being direct
• What to negotiate on a term sheet, and what doesn't matter
• For international founders: how to set up, position, and raise in the US
Meet the Speakers
🎤 Matt Caspari @deeptechvc — Managing Partner, @alumniventures
Investment Focus: Deep Tech from seed to pre-IPO
Matt leads the Deep Tech and Strawberry Creek Ventures funds at Alumni Ventures, backing mission-driven founders across agriculture, AI, aviation, biotech, defense, energy, longevity, robotics, and space. A two-time venture-backed founder/CEO — including founding CEO of Aurora Biofuels (100+ employees, $100M+ raised, acquired by Reliance Industries) — and a former leader on Nike's innovation team.
🎤 Victoria Smith — Partner at @ZacuaVentures
Investment Focus: PropTech, ConTech, AI-native software, marketplaces, consumer & enterprise SaaS
Victoria was an early hire at both Jackson Square Ventures and Zacua Ventures, where she led pre-seed investments in software for the built environment and ran Launchpad, JSV's earliest-stage vehicle for student-led startups. A former founder of an acquired company herself, she brings both the operator's and the investor's perspective to the table.
🎤 Allen Smith — Founder & Managing Partner, @Musa_Capital
Investment Focus: Early-stage, tech-enabled businesses built by diverse founding teams
Allen is Founder and Managing Partner at Musa Capital, an early-stage firm investing in diverse founding teams building tech-enabled businesses. He brings 10+ years in go-to-market and sales operations from LinkedIn, Microsoft, and Waterstone Management Group, where he built and scaled major commercial initiatives.
Moderator
🎤 Gary Gardner — Founder & CEO, Lead Generation Hubs
Gary is a seasoned sales leader and Army Reserve Captain building a platform to empower sales professionals. With a PhD in Organization and Management and experience leading high-performing teams as VP of Sales at Hyqoo and Toptal, he brings both academic and practical expertise to business development.
📅 Date & Time: Thursday, June 18, 2026 | 10:00 AM – 11:00 AM
📍 Location: 75 Arbor Road, Menlo Park, CA
Who should attend? If you're fundraising now — or about to start — and want to understand how investors actually decide, from the first meeting through the partnership discussion to the term sheet, this session is for you. International founders raising in the US will find it especially useful.
Details and sign up at: techweekend.org
Matt Caspari retweeted
With a nod to @leopoldasch, we're releasing Biological Awareness - our musings on the next decade at the frontiers of AI and life sciences.
Six ideas we explore:
→ Task-specific experimental tokens are the new gold in biology
→ Bio AI data factories will pioneer new business models
→ Smoothing out the jagged frontier for pharma enterprises is where fortunes will be made
→ Clinical trial intelligence will be financialized before it is operationalized
→ The bioweapons threat is real, accelerating, and underpriced
→ The BIOSECURE Act will fundamentally reshape supply chains
2026 marks ten years of Obvious investing at this intersection. A lot has happened. Even more is coming.
Big thanks to: @kyosu, @syntenyAI, @GabriCorso, @inductivebio, @mithrl_ai , @instancebio , @strangemonad, @exnx and many others for their help!
Matt Caspari retweeted
I'm super excited to announce our $7.2M seed round + a strategic collaboration with @PacBio! Together, we'll be generating long-read, bulk-RNA sequencing directly from patient tumours spanning multiple cancer indications.
This is extremely rich data that will be used to further train and evaluate our models. @blankbio_, we are focused on training RNA foundation models that can learn and predict disease progression and treatment response in patients. These are the biological insights that will enable us to design smaller, more efficient clinical trials with higher success rates.
Huge thank you to all of our investors who have been amazing supporters from the beginning. For more details, please check out the links below.
Press release: blank.bio/seed-announcement
Blog from the team: blank.bio/accelerate-clinica…
We're hiring: ycombinator.com/companies/bl…
Today, we’re excited to announce our $7.2M seed round alongside a strategic collaboration with @PacBio! At Blank Bio, we help pharma make more informed decisions in clinical trials by capturing the biology that makes each patient’s tumour unique.
We do this by training RNA foundation models to learn the patterns that shape disease progression and how patients respond to treatment. In our collaboration with @PacBio, we will generate long-read, bulk RNA-sequencing data from patient tumour samples across multiple indications. This dataset will be used to further train and evaluate our models.
Our models are currently focused on two main applications. First, we predict how a patient’s disease is likely to progress over time from their molecular profile. Through the FDA-recommended approach of covariate adjustment, these RNA prognostic scores can help clinical development teams design trials that reach statistical power with fewer patients. Second, we’re working to help pharma teams understand biological differences between patients so they can identify who is most likely to respond to a given therapy.
We are thankful to @definevc, @LeonisCapital, Nova Threshold, @ripple_ventures, @SignalFire, @ycombinator, and other investors for being early supporters in our vision. This financing will support the continued development of our foundation models, expanded collaborations with pharma, and growing our patient-level datasets.
Read the press release: blank.bio/seed-announcement
Read the blog from the team: blank.bio/accelerate-clinica…
Learn more about Blank Bio: blank.bio
Matt Caspari retweeted
I've been posting less and writing more. I've found it helpful to slow everything down and take the time for proper reflection.
Today I'm putting out a review of the last quarter:
Growing AI Anxiety
Turning LLMs into Computers
Anthropic and the Department of War
Iranian Conflict
The Incoming Techlash
It's easy to feel like the response to this is for tech to "get tough"
But I want to encourage the next generation to do something simple: keep your soul
Matt Caspari retweeted
Silent Ventures is privileged to co-lead @SwarmAero's Series A alongside our friends at @TwoSigmaVC. We're happy to welcome @ScribbleVC @friendsfamcap and several others to this journey. Swarm has quietly developed one of the most advanced Group 5 drones in market, in addition to a leading autonomous command and control platform. These capabilities are critical for US defense and Western sovereignty. Congrats to the founding team on this achievement. Americans are safer because of the good people at Swarm.
cc @foundersfund @khoslaventures @constructcap @MaCVentureCap @QuietCapital @alumniventures
Modern conflicts are decided in the air. Swarm Aero is building a radically effective way to scale air power.
We're proud to share that we've raised $35 million in Series A funding, led by @TwoSigmaVC and @SilentVentures and joined by our seed investors @khoslaventures, @ScribbleVC, @friendsfamcap, @constructcap, @coatuemgmt, @foundersfund, @alumniventures, and @MaCVentureCap! This brings total capital raised to $59M to accelerate the deployment of our large UAV and the swarm software that enables drones to be controlled at scale.
While smaller drones pack smaller punches and require assistance to get to the fight, our large, multimission UAV can cover long distances and defeat high-value targets. Designed to manufacture at unprecedented volume and cooperate with superhuman dexterity, our UAV achieves asymmetric impact at dramatically lower cost than traditional aircraft.
The future world order depends on who controls air power. Swarm is building the technologies needed for deterrence and dominance in the 21st century. And we’re hiring!
Read more in @axios' Future of Defense exclusive on the raise (thank you @demarest_colin!) and our press release:
axios.com/2026/03/11/swarm-a…
businesswire.com/news/home/2…
Matt Caspari retweeted
Modern conflicts are decided in the air. Swarm Aero is building a radically effective way to scale air power.
We're proud to share that we've raised $35 million in Series A funding, led by @TwoSigmaVC and @SilentVentures and joined by our seed investors @khoslaventures, @ScribbleVC, @friendsfamcap, @constructcap, @coatuemgmt, @foundersfund, @alumniventures, and @MaCVentureCap! This brings total capital raised to $59M to accelerate the deployment of our large UAV and the swarm software that enables drones to be controlled at scale.
While smaller drones pack smaller punches and require assistance to get to the fight, our large, multimission UAV can cover long distances and defeat high-value targets. Designed to manufacture at unprecedented volume and cooperate with superhuman dexterity, our UAV achieves asymmetric impact at dramatically lower cost than traditional aircraft.
The future world order depends on who controls air power. Swarm is building the technologies needed for deterrence and dominance in the 21st century. And we’re hiring!
Read more in @axios' Future of Defense exclusive on the raise (thank you @demarest_colin!) and our press release:
axios.com/2026/03/11/swarm-a…
businesswire.com/news/home/2…
Matt Caspari retweeted
Sharing this publicly––hope it's not needed but helps you if it is.
Lux team sent this memo to all Lux family founders yesterday
"We send notes like this not because something is wrong, but because the COST of preparation is trivially LOW and the VALUE of being positioned well is asymmetrically HIGH. This isn’t a macro call. It’s a set of observations about correlated risks that are worth your attention. And a set of practical suggestions regardless of whatever happens next."
Matt Caspari retweeted
Some benchmarks for deep tech company fundraising across 900+ rounds raised by US startups in 2025.
Scattered thoughts:
Deep tech companies took in 36% of total funding this year to Carta companies. That's up from only 17% a decade ago. Deep tech is riding a wave.
There has been a resurgence of interest into specific deep tech categories lately (American Dynamism, defense+aerospace, etc). Maybe some of that is the idea that moats in software are declining in the age of AI.
Not every deep tech category had a good year. Medical Device funding continued to struggle in 2025 and IoT was flat.
While deep tech is not quite as SF-centric as software startups tend to be, this data still reflects more rounds in the Bay Area than anywhere else.
Deep tech companies, particularly Biotech, used to favor convertible notes over SAFEs. That has flipped in recent years, with every deep tech sector now solidly seeing more volume at early stages on SAFEs.
AI is in this data but not to the same extent as in software-only companies.
Deep tech startup fundraising is usually more dilutive at the early stages than software-only fundraising (meaning a founder will have to sell more of the company for a similar amount of money).
Interestingly, the total amount of capital needed for a deep tech startup to make it all the way to IPO is not usually much more than the total capital needed for a software startup. So more dilutive upfront, but not always more capital-intensive.
Regulatory concerns play a bigger role in many deep tech sectors than in pure software, but interaction with the government on state and federal levels is getting fractionally easier for some over time.
Matt Caspari retweeted
We just raised a $20M seed round to build the largest bank in the world.
Kontigo crossed $30M in annual revenue, $1B in payment volume, and 1M users in under 12 months, with a team of six engineers and one designer.
We are the fastest-growing stablecoin neobank in the world.
Any individual or business on earth can:
- Earn 10% yield on their digital dollars.
- Get a stablecoin card with bitcoin cashback.
- Activate a USDT credit line.
- Invest in tokenized U.S. stocks.
- Open an international account for free.
This is a real-world use case of crypto. No casinos, no jargon, just normal people who don’t even know what USDC or USDT is.
We’re, once and for all, democratizing access to basic finance and giving 4.8 billion people the ability to hold a stable currency (USDC) alongside a wealth creator (BTC).
The equation is simple: they invest in BTC, they hold USDC, and they spend in local stablecoins. More than a thousand businesses and a million users are already doing this.
They connect their local bank, card, or payment method and start moving funds globally, instantly, and without limits.
No matter the corridor. U.S. ↔ LatAm, LatAm ↔ Asia, Asia ↔ Europe, U.S. ↔ Africa, Europe ↔ LatAm. We’ve them all.
Just imagine how much faster Revolut would’ve grown if they didn’t have to get individual banking licenses in each of the 50 countries they’ve launched in. That’s @kontigo_app
You simply can’t outcompete the fact that our backend, database, and infrastructure run on the freaking blockchain: 24/7, at a fraction of the cost, open, permissionless.
It’s a whole new game, different incentives, and a new technological paradigm.
Thanks to all the early supporters! We’re proud to partner with the best: @t_blom & @harjtaggar from @ycombinator ; @hthieblot & @FurqanR from @fdotinc ; @davefontenot from @hf0 ; @HoolieG from @cbventures & @jessepollak from @base ; Saurabh and Grace from DST ; also @GoodwaterCap @Soma_Capital @pioneer_fund @transposevc @alumniventures @m_franceschetti @EvanWeb3 @metavarce @davecyen Tom Brown, Oliver Jung, Ricardo Schäfer, Andrej Henkler, Yi Shi, Philippe Teixeira.
Some people said the fintech era was over…


































